Cost-effectiveness of golimumab versus infliximab and adalimumab for the treatment of moderate to severe ulcerative colitis
May 1, 2014, 00:00
10.1016/j.jval.2014.03.232
https://www.valueinhealthjournal.com/article/S1098-3015(14)00283-6/fulltext
Title :
Cost-effectiveness of golimumab versus infliximab and adalimumab for the treatment of moderate to severe ulcerative colitis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)00283-6&doi=10.1016/j.jval.2014.03.232
First page :
A38
Section Title :
Gastrointestinal Disorders
Open access? :
No
Section Order :
1264